Coherus Oncology (CHRS) Receivables - Other (2013 - 2026)

Coherus Oncology's Receivables - Other history runs 6 years deep, the most recent figure standing at $446000.0 for Q1 2026.

• In Q1 2026, Receivables - Other fell 77.1% year-over-year to $446000.0; the TTM figure through Mar 2026 stood at $446000.0 (down 77.1% YoY), while the FY2025 annual figure was $603000.0, down 94.52% from the prior year.
• Receivables - Other came in at $446000.0 for Q1 2026 at Coherus Oncology, down from $603000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $241.3 million in Q3 2025 to a low of $446000.0 in Q1 2026.
• A 3-year average of $63.5 million and a median of $31.2 million in 2024 frame the typical range for Receivables - Other.
• On a YoY basis, Receivables - Other climbed as much as 672.23% in 2025 and fell as far as 94.52% in 2025.
• Coherus Oncology's Receivables - Other stood at $11.0 million in 2024, then slumped by 94.52% to $603000.0 in 2025, then dropped by 26.04% to $446000.0 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $446000.0, $603000.0, and $241.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison